In her essay in The Washington Post, Dr. Pamela Munster recounts her family's history with cancer associated with a mutation in the BRCA2 gene. She details her father's extraordinary journey with pancreatic cancer, one of the most aggressive and deadly cancers. (11/27/18)
The National Comprehensive Cancer Network (NCCN) brings together a national panel of experts that create guidelines for cancer screening, prevention and treatment.
NCCN guidelines reccommend genetic testing for all people with pancreatic cancer, regardless of age of diagnosis or family history. Up to 10% of people with pancreatic cancer will test positive for an inherited mutation in a gene that may affect their treatment. Genetic test results may also help relatives understand and manage their risk for cancer.
The NCCN gives no specific screening guidelines for previvors with a BRCA2 mutation, but it does notes that "screening may be individualized based on cancers observed" in the family and that investigational screening protocols should be considered.
Th CAPS consortium published a consensus paper in 2013 indicating that pancreatic screening is justified for BRCA2 carriers and other high-risk people with one or more affected first-degree relatives (i.e. parent, sibling and/or child).
As part of their provisional clinical opinion on pancreatic cancer, ASCO indicates that:
"Benefits and limitations of pancreatic cancer screening should be discussed with individuals whose family history meets criteria for FPC [familial pancreatic cancer] and/or genetic susceptibility to pancreatic cancer."
The clinical trials listed below are currently enrolling pancreatic cancer patients. With FORCE's research study tool you can search for additional studies enrolling people with pancreatic cancer.
The clinical trials listed below are currently enrolling people at high risk for pancreatic cancer due to an inherited mutation or family history of pancreatic cancer. With FORCE's research study tool you can search for additional studies enrolling people at high risk for pancreatic cancer.
NCT02478892: Screening for PDAC in BRCA1/2 Patients. This study is open to people with an inherited mutation and family history of cancer. The study involves undergoing endoscopic ultrasound to detect pancreatic cancer.
GENetic Education Risk Assessment and TEsting Study (GENERATE). This study involves genetic testing for people with relatives who have been diagnosed with pancreatic cancer.
FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.